PDGF/PDGFR Effects in Osteosarcoma and the "add-on" Strategy

Overview

Journal Clin Sarcoma Res

Publisher Biomed Central

Date 2018 Aug 8

PMID 30083310

Citations 15

Authors

Jie Xu

Lu Xie

Wei Guo

Affiliations

Soon will be listed here.

Abstract

New treatment options for advanced osteosarcoma have remained limited. The platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor (PDGFR) pathway plays an important role in the development and metastasis of osteosarcoma, via either direct autocrine stimulation of tumor cells, or paracrine stimulation on tumor stromal cells. It promotes angiogenesis to overcome hypoxia in the tumor microenvironment, and modulates tumor interstitial fluid pressure to control the influx and efflux of other agents. Targeting the PDGF/PDGFR pathway is a promising therapeutic method to overcome drug resistance and improve patients' outcome in osteosarcoma. Further evidence is needed to define the detailed mechanism. Results from clinical trials using PDGF/PDGFR inhibitor as a single agent were disappointing, both in osteosarcoma and soft tissue sarcoma. However, when combined with other agents, named as "add-on" strategy, a synergistic antitumor effect has been confirmed in soft tissue sarcoma, and should be attempted in osteosarcoma.

Citing Articles

NGF-TrkA Axis Enhances PDGF-C-Mediated Angiogenesis in Osteosarcoma via miR-29b-3p Suppression: A Potential Therapeutic Strategy Using Larotrectinib.

Hou S, Cheng C, Chen W, Chang E, Lin C Life (Basel). 2025; 15(1).

PMID: 39860039 PMC: 11766545. DOI: 10.3390/life15010099.

Combination of Sintilimab and Anlotinib for Metastatic Osteosarcoma: A Case Report.

Tang G, Zhang Q, Wang F, Zhang H, Qi Y Onco Targets Ther. 2024; 17:661-665.

PMID: 39161887 PMC: 11331146. DOI: 10.2147/OTT.S464678.

IRF5 suppresses metastasis through the regulation of tumor-derived extracellular vesicles and pre-metastatic niche formation.

Roberts B, Li D, Somerville C, Matta B, Jha V, Steinke A Sci Rep. 2024; 14(1):15557.

PMID: 38969706 PMC: 11226449. DOI: 10.1038/s41598-024-66168-w.

: NF-κB Inhibition as an Alternative to Overcome Osteosarcoma Heterogeneity.

Medeiros M, Guenka S, Bastos D, Oliveira K, Brassesco M Pharmaceuticals (Basel). 2024; 17(6).

PMID: 38931401 PMC: 11206879. DOI: 10.3390/ph17060734.

Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients.

Zou C, Huang R, Lin T, Wang Y, Tu J, Zhang L Front Oncol. 2024; 14:1382276.

PMID: 38841159 PMC: 11150704. DOI: 10.3389/fonc.2024.1382276.

References

Heldin C . Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 2013; 11:97. PMC: 3878225. DOI: 10.1186/1478-811X-11-97. View

Grignani G, Palmerini E, Dileo P, Asaftei S, DAmbrosio L, Pignochino Y . A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2011; 23(2):508-16. DOI: 10.1093/annonc/mdr151. View

Sulzbacher I, Birner P, Dominkus M, Pichlhofer B, Mazal P . Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome. Pathology. 2010; 42(7):664-8. DOI: 10.3109/00313025.2010.520310. View

Ostman A . PDGF receptors in tumor stroma: Biological effects and associations with prognosis and response to treatment. Adv Drug Deliv Rev. 2017; 121:117-123. DOI: 10.1016/j.addr.2017.09.022. View

Pratt C . Treatment of osteosarcoma 1972-1997: an American perspective. Pediatr Hematol Oncol. 1998; 15(3):207-10. DOI: 10.3109/08880019809028786. View

Ma Q, Zhang Y, Liu T, Jiang K, Wen Y, Fan Q . Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma. Cancer Biol Ther. 2017; 18(3):177-185. PMC: 5389426. DOI: 10.1080/15384047.2017.1294285. View

Egas-Bejar D, Anderson P, Agarwal R, Corrales-Medina F, Devarajan E, Huh W . Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis. Oncoscience. 2014; 1(2):167-179. PMC: 4128257. DOI: 10.18632/oncoscience.21. View

Tejada M, Yu L, Dong J, Jung K, Meng G, Peale F . Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res. 2006; 12(9):2676-88. DOI: 10.1158/1078-0432.CCR-05-1770. View

Yoshida D, Kim K, Noha M, Teramoto A . Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in human glioblastoma cells. J Neurooncol. 2005; 76(1):13-21. DOI: 10.1007/s11060-005-3279-0. View

10.

Loizos N, Xu Y, Huber J, Liu M, Lu D, Finnerty B . Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther. 2005; 4(3):369-79. DOI: 10.1158/1535-7163.MCT-04-0114. View

11.

Chugh R, Wathen J, Maki R, Benjamin R, Patel S, Meyers P . Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a bayesian hierarchical statistical model. J Clin Oncol. 2009; 27(19):3148-53. DOI: 10.1200/JCO.2008.20.5054. View

12.

Bond M, Bernstein M, Pappo A, Schultz K, Krailo M, Blaney S . A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer. 2007; 50(2):254-8. DOI: 10.1002/pbc.21132. View

13.

Baxter R, Secrist J, Vaillancourt R, Kazlauskas A . Full activation of the platelet-derived growth factor beta-receptor kinase involves multiple events. J Biol Chem. 1998; 273(27):17050-5. DOI: 10.1074/jbc.273.27.17050. View

14.

Heldin C . Targeting the PDGF signaling pathway in the treatment of non-malignant diseases. J Neuroimmune Pharmacol. 2013; 9(2):69-79. DOI: 10.1007/s11481-013-9484-2. View

15.

McGary E, Weber K, Mills L, Doucet M, Lewis V, Lev D . Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res. 2002; 8(11):3584-91. View

16.

Pessetto Z, Ma Y, Hirst J, von Mehren M, Weir S, Godwin A . Drug repurposing identifies a synergistic combination therapy with imatinib mesylate for gastrointestinal stromal tumor. Mol Cancer Ther. 2014; 13(10):2276-87. PMC: 4185217. DOI: 10.1158/1535-7163.MCT-14-0043. View

17.

Pender A, Jones R . Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma. Clin Pharmacol. 2017; 9:159-164. PMC: 5720043. DOI: 10.2147/CPAA.S130178. View

18.

Sulzbacher I, Traxler M, Mosberger I, Lang S, Chott A . Platelet-derived growth factor-AA and -alpha receptor expression suggests an autocrine and/or paracrine loop in osteosarcoma. Mod Pathol. 2000; 13(6):632-7. DOI: 10.1038/modpathol.3880109. View

19.

Lagmay J, Krailo M, Dang H, Kim A, Hawkins D, Beaty 3rd O . Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward. J Clin Oncol. 2016; 34(25):3031-8. PMC: 5012712. DOI: 10.1200/JCO.2015.65.5381. View

20.

Wang Y, Mandal D, Wang S, Hughes D, Pollock R, Lev D . Inhibiting platelet-derived growth factor beta reduces Ewing's sarcoma growth and metastasis in a novel orthotopic human xenograft model. In Vivo. 2009; 23(6):903-9. View